Efrat Gilad

Efrat Gilat is Maabarot Products Ltd.’s CEO since September 2017, Algaia board member and expert in infant nutrition.

She previously served 8 years as CEO of the leading Infant nutrition business of Nestle Nutrition in Israel, called Materna™ (a joint venture of Nestlé and Maabarot Products Ltd). 

Efrat benefits from a vast experience in the B-to-C and infant food industry. During those years at Materna™, Efrat achieved significant top line and bottom line growth while strengthening Marterna™’s brand leadership position.

Efrat holds a MBA from University of Derby and a B.Sc. from the Israel Institute of Technology.

Eyal Shalmon

Eyal Shalmon is Maabarot product Ltd Chairman since 2014 and Algaia's Chairman of the Board.

Eyal Shalmon is also member of Kibbutz Maabarot, a majority shareholder of Maabarot Products Ltd. Mr Shalmon is chairman of both Maabarot and Lordan Coils Boards.

Previously, over the last 16 years, Eyal Shalmon served as CFO and M&A Director with several listed companies such as Maabarot and EMT and has a strong background in strategy, finance and business development. Mr Shalmon holds an MBA from Heriot-Watt University.

Fabrice Bohin

Fabrice BOHIN, is ALGAIA’s CEO and member of the Board.

Fabrice has over 24 years’ experience in the Specialty Food Ingredient sector, servicing the FMCG market through a B2B approach. He started his career at Rhodia (now Solvay) in 1994 where he worked mostly for its Food ingredient division in various roles such as Application lab manager, Business Development, Marketing, Strategy, Business Development Director (M&A), Corporate Account Leader, Vice General Manager and International Business Director for product lines ranging from lactic Bacteria’s, Biogums, Seaweed Extracts, Plant Extracts and Food systems.

In 2004, he joined Cargill as Business Development Director to help the company entering into the specialty food ingredient sector through external and internal growth. After two acquisitions in a row, Cargill became one of the top four leaders in the Texturizing Solution arena and Fabrice was offered the position of Global Business Director of Cargill newly integrated Hydrocolloid portfolio composed of Pectin (fruit extracts), Carrageenans & Alginates (seaweed extracts), LBG (plant extracts) and Biogums (functional polysaccharides produced through fermentation). Starting 2012, he was also in charge of Cargill Texturizing Solutions functional food system business for Europe.

In Cargill, Fabrice was managing a business of over 300m$ revenue where both top and bottom line improved double to triple digits over the period. He joined ALGAIA in June 2014 as the new CEO of the company.

Eric Marty

Eric MARTY is Investment Director at Demeter-Emertec and historic investor in the company.

Eric Marty represents Demeter-Emertec in Algaia's Board. He is graduated from the prestigious French chemical engineering school Chimie-Paris Tech. 

Between 1990 and 2004, he held several positions within large chemical groups such as Rhodia (now Solvay) or refining industry player like IFPE in Europe and Latin America. 

Since 2004, Mr. Marty is a partner and member of the managing board of Emertec Gestion, now Demeter-Emertec, the major European private equity player investing in early stage innovative technological companies and being today the largest investor within Algaia.

M. Marty currently serves on the board of directors of innovative biotech and nutrition companies like Algaia, Alderys (Biotech) and Olygose (soluble fiber from vegetables) as well as on the boards of several French companies in the field of Energy and environmental technologies.

Emertec Gestion was one of the early investor in Fermentalg (micro-algae based products for Food, feed and other applications) that was successfully put on the stock market in 2014 and Ynsect (developing value added components from insects).

Celia Hart

Celia HART is Partner at Supernova Invest, third largest and historic investor in Algaia.

Celia Hart is Supernova Invest's representative on the board of Algaia. 

Celia has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and has since carried out the investments in several companies operating mainly in life sciences. She serves (or has served) on the Boards of several companies including Algaia, Bioaxial, Diabeloop, Fermentalg, Keranova, Uromems and Theranexus.

Prior to that Celia mainly worked for Cambridge Antibody Technology one of the most successful UK biotechnology companies (now Medimmune following its acquisition by Astra Zeneca) holding different managing and product development positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in including some in collaboration with international biotechnology or pharmaceutical partners. 

Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France).

Gilles Lagarde

Gilles LAGARDE is Specialist in Food Ingredients Industry and acts as independent board member.

Gilles Lagarde has more than 30 years of experience in the fields of Fermentation and Extraction; he is one of the most recognized senior leaders of the specialty food ingredients industry. 

During his career, he was VP and General Manager of Sanofi Bio-Industries (Cultures and Enzymes Division) and SBI/SKW (Food Ingredients and Additives Division). 

In 1999, he finally joined NEOVA (formerly known as Inovatech Bio-Products, a specialty group dedicated to the development of ingredients for the healthcare, food and feed industries) as Executive VP and Shareholder. He was also the founder and the first President of EFFCA (European Food & Feed Cultures Association).

Patrick Mewton

Patrick MEWTON is the founder of CLOTILDE LIMITED, an Independent Corporate Finance Advisory House dedicated to the Global Agribusiness and Value-Added Ingredients Sectors, and acts as independent board member.

Patrick Mewton has 20 years of Investment Banking experience during which time he has predominantly focused on Mergers & Acquisitions across the global Business-to-Business sector where he has worked on in excess of 100 transactions across every continent.

During his career Patrick was a shareholder at McQueen Limited, the leading European Consumer –focused M&A house, and became a Managing Director at Houlihan Lokey following its acquisition of McQueen Limited in 2015. Previously to McQueen, Patrick was the Global Head of Commodities & Ingredients M&A at Rabobank/Rothschild and he has also worked at ABN AMRO and Deutsche Bank. In 2016 Patrick founded Clotilde Limited.